Comparison of ATLG and ATG for Immune Reconstitution After Allo-HSCT for Hematologic Malignancy
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Allogeneic hematopoietic stem cell transplantation is the only curative treatment for malignant hematologic diseases. However, immune rejection is a major limitation in its application. In the "Beijing Protocol", the use of granulocyte colony-stimulating factor (G-CSF) in combination with anti-thymocyte globulin (ATG) can achieve "everyone has a donor". The use of ATG, however, can interfere with the recovery of immune function after transplantation, increasing the risk of life-threatening complications such as viral infections or graft-versus-host disease. Rabbit anti-human T-lymphocyte immunoglobulin (ATLG) is currently approved for the prevention of organ transplant rejection, which is produced differently from ATG. Previous studies have shown that transplant preconditioning with ATLG is effective in preventing graft-versus-host disease and even reduces the incidence of cytomegalovirus, etc. after transplantation. In this study, we will prospectively apply containing ATLG in a cohort of allogeneic hematopoietic stem cell transplantation for malignant hematologic diseases and dynamically observe the state of immune reconstitution of patients after transplantation. We will also compare it with a matched cohort of conventional combined ATGs during the same period to explore the impact of ATLG on immune reconstitution after transplantation.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Potwierdzony nowotwór krwi (białaczka, chłoniak lub zespół mielodysplastyczny)
- •Pierwszy raz przygotowujesz się do przeszczepu szpiku od innego dawcy
- •Ogólny stan zdrowia pozwala na przyjęcie leczenia
- •Prawidłowa funkcja nerek, serca i płuc
- •Spodziewana przeżywalność dłuższa niż 12 tygodni
- •Dobrowolna zgoda na udział w badaniu
✗ Disqualifies
- •Poprzednie leczenie podobnymi lekami (ATG, ALG lub ATLG) w ciągu ostatnich 6 miesięcy
- •Alergia na składniki ATLG lub ATG
- •Niekontrolowana zakażenie (bakteryjne, wirusowe lub grzybiczne)
- •Ciąża, karmienie piersią lub brak chęci stosowania antykoncepcji
- •Uczestnictwo w innym badaniu klinicznym w ostatnich 30 dniach
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 5, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Peking University First Hospital
Beijing, China
Trial contact
Jialin Zhu, MD
Bingjie Wang, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/6/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.